Evidence map›Paper›PMID 33049112›Full record

ArticleJournal of thrombosis and haemostasis : JTH2021

Laboratory variability in the diagnosis of type 2 VWD variants.

Stefanie DiGiandomenico, Pamela A Christopherson, Sandra L Haberichter, Thomas C Abshire, Robert R Montgomery, Veronica H Flood, Zimmerman Program Investigators

Open access · greenAbstract read
In one paragraph

Article in Journal of thrombosis and haemostasis : JTH, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Von Willebrand disease type 2M: Correlation between genotype and phenotype.Journal of thrombosis and haemostasis : JTH · 2022
    Article
  10. Article
  11. Von Willebrand Disease: Current Status of Diagnosis and Management.Hematology/oncology clinics of North America · 2021
    Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Stefanie DiGiandomenicoDepartment of Pediatrics, Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Pamela A ChristophersonVersiti Blood Research Institute, Milwaukee, WI, USA.
Sandra L HaberichterDepartment of Pediatrics, Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Thomas C AbshireDepartment of Pediatrics, Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Robert R MontgomeryDepartment of Pediatrics, Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Veronica H FloodDepartment of Pediatrics, Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.ORCID 0000-0001-8998-6838
Zimmerman Program Investigators
Medical College of Wisconsin · USChildren's Hospital of Wisconsin · USVersiti Blood Center of Wisconsin · US

Funding

Zimmerman Program for the Molecular and Clinical Biology of VWDP01HL081588 · NHLBI · VERSITI WISCONSIN, INC. · PI MONTGOMERY, ROBERT R · 2005 to 2016
$19.3M
Zimmerman Program on the Biology of VWDP01HL144457 · NHLBI · VERSITI WISCONSIN, INC. · PI MONTGOMERY, ROBERT R · 2019 to 2023
$13.3M
Comparative Effectiveness in the Diagnosis of VWDR01HL112614 · NHLBI · VERSITI WISCONSIN, INC. · PI ABSHIRE, THOMAS CALVIN, MONTGOMERY, ROBERT R · 2013 to 2018
$4.1M
Molecular Interactions of FVIII and VWFR01HL139847 · NHLBI · VERSITI WISCONSIN, INC. · PI MONTGOMERY, ROBERT R · 2018 to 2021
$2.3M
Mechanism of Type 4 Collagen Interactions with Von Willebrand FactorR01HL126810 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI FLOOD, VERONICA H · 2016 to 2020
$1.9M
VWF - Mechanisms of RegulationR01HL136430 · NHLBI · VERSITI WISCONSIN, INC. · PI HABERICHTER, SANDRA · 2018 to 2021
$1.7M
NHLBI NIH HHS P01 HL081588NHLBI NIH HHS P01 HL144457NHLBI NIH HHS R01 HL112614NHLBI NIH HHS R01 HL126810NHLBI NIH HHS R01 HL136430NHLBI NIH HHS R01 HL139847
6 · The paper itself

Abstract

Essentials Patients with von Willebrand disease were enrolled in our study. Type 2 VWD diagnoses were based on original test results. Repeat evaluation resulted in many patients receiving a different type 2 diagnosis. Some genetic variants were particularly likely to move type 2 subcategories. ABSTRACT: Introduction Type 2 von Willebrand disease (VWD) refers to patients with a qualitative defect in von Willebrand factor. Accurate diagnosis of type 2 VWD subtypes can be challenging. Aim of the study To compare the historical diagnosis of type 2 VWD with current laboratory testing. Methods Subjects were enrolled in the Zimmerman Program either because of a preexisting diagnosis of VWD (retrospective cohort) or from evaluation for bleeding symptoms or suspected VWD (prospective cohort). Original diagnosis was assigned by the local center and central diagnosis was based on central laboratory testing. Results Two hundred and seventeen index cases in the retrospective cohort and 35 subjects in the prospective cohort carried a local diagnosis of type 2 VWD (29% and 6% of enrolled index cases, respectively). In the retrospective cohort, the diagnosis was confirmed in 66% of cases with a preexisting diagnosis of 2A, 77% 2B, 54% 2M, and 72% 2N. In the prospective cohort, 31% were confirmed 2A, 60% 2B, 23% 2M, and 100% 2N. Several genetic variants were repeatedly implicated in subjects with changed diagnosis: p.M1304R, p.R1315C, p.R1374C, and p.R1374H. Conclusions Both the prospective and retrospective cohorts demonstrated consistent variation in subjects whose diagnosis changed between 2A, 2B, and 2M. The importance of accurately diagnosing type 2 VWD may be most significant in the 2B subtype given potential concerns with the use of desmopressin in type 2B VWD. Some genetic variants appear in multiple types of VWD, making specific diagnoses challenging.

Indexed as

von Willebrand Diseasesvon Willebrand Disease, Type 2HumansProspective StudiesRetrospective Studiesvon Willebrand Factorvon Willebrand Factorgeneticmedical laboratory sciencepolymorphismristocetinVon Willebrand diseaseVon Willebrand factor

Identifiers

PMID33049112
PMCPMC7790985
OpenAlexW3092116463

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.